Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alpha v beta 3 expressed on human tumor cells

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lanza, P.
  • Felding, Brunhilde
  • Ruggeri, Zaverio
  • Zanetti, M.
  • Billetta, R.

publication date

  • 1997

journal

  • Blood Cells Molecules and Diseases  Journal

abstract

  • Two antigenized antibodies (AgAbs) were engineered to express peptidic Arg-Gly-Asp (RGD) motifs present in extracellular matrix molecules. The RGD tripeptide sequence was inserted in the third hypervariable loop of an immunoglobulin human/mouse chimeric heavy chain gene as a single or three repeat yielding two antibodies termed gamma1RGD and gamma1(RGD)3, respectively. The antibodies were used to target specific cell-surface receptors of the integrin type expressed by three human tumor cell lines, a melanoma (M21), and osteosarcoma (KRIB) and a fibroblastoma (WI-38). Based on in vitro adhesion assays and flow cytometric analysis, we found that all three cell lines interacted with gamma1(RGD)3 but not with gamma1RGD. Binding of tumor cells to surface-immobilized gamma1(RGD)3 was inhibited in a dose-dependent manner by the RGD-containing synthetic peptides GdRGDSP and RGDS. These synthetic peptides, but no a GDR-containing control peptide, interfered with the binding of tumor cells to surface-immobilized human fibronectin. In their soluble form, neither fibronectin nor gamma1(RGD)3 inhibited tumor cell adhesion to surface-immobilized fibronectin. Gamma1(RGD)3 specifically recognized integrin alphavbeta3 based on two criteria: reactivity with purified integrin receptors and binding to variants of M21 melanoma cells expressing alphavbeta3, alphaIIbbeta3 or no beta3 integrins, respectively. Collectively, our results indicate that the (RGD)3 loop in the antigenized antibody mimics the ligand function of natural extracellular matrix proteins and has a restricted receptor specificity for the alphavbeta3 integrin which is not inherent to short RGD containing peptides.

subject areas

  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Cell Adhesion
  • Fibronectins
  • Genes, ras
  • Genetic Variation
  • Humans
  • Immunoglobulin Heavy Chains
  • Mice
  • Molecular Sequence Data
  • Mutagenesis, Insertional
  • Oligopeptides
  • Peptide Fragments
  • Protein Conformation
  • Receptor-CD3 Complex, Antigen, T-Cell
  • Receptors, Vitronectin
  • Recombinant Fusion Proteins
  • Transfection
  • Tumor Cells, Cultured
scroll to property group menus

Research

keywords

  • RGD
  • adhesion
  • alpha nu beta 3
  • antibody
  • antigenized
  • fibroblastoma-WI-38
  • integrin
  • melanoma-M21
  • osteosarcoma-KRIB
  • tumor cells
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1079-9796

Digital Object Identifier (DOI)

  • 10.1006/bcmd.1997.0140

PubMed ID

  • 9268674
scroll to property group menus

Additional Document Info

start page

  • 230

end page

  • 241

volume

  • 23

issue

  • 12

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support